ACADIA Pharmaceuticals Inc. (ACAD)

Market Cap	2.85B
Revenue (ttm)	957.80M
Net Income (ttm)	226.45M
Shares Out	166.79M
EPS (ttm)	1.36
PE Ratio	12.55
Forward PE	29.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	808,371
Open	17.16
Previous Close	17.19
Day's Range	16.92 - 17.22
52-Week Range	14.15 - 20.68
Beta	0.43
Analysts	Buy
Price Target	24.00 (+40.6%)
Earnings Date	May 7, 2025

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 27, 2004
• Employees: 654
• Stock Exchange: NASDAQ
• Ticker Symbol: ACAD
• Website: https://www.acadia.com

Analyst Forecast

According to 17 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is $24.0, which is an increase of 40.60% from the latest price.

Price Target

$24.0

(40.60% upside)

Analyst Consensus: Buy